
Shattuck Labs, Inc. (NASDAQ:STTK – Free Report) – Equities research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for Shattuck Labs in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.55) for the year, down from their previous forecast of ($0.42). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at ($0.70) EPS.
Shattuck Labs (NASDAQ:STTK – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04).
Check Out Our Latest Stock Report on STTK
Shattuck Labs Price Performance
Shattuck Labs stock opened at $4.62 on Monday. Shattuck Labs has a 12 month low of $1.72 and a 12 month high of $8.33. The company has a fifty day moving average price of $6.00 and a two-hundred day moving average price of $6.02. The company has a market cap of $463.68 million, a PE ratio of -9.06 and a beta of 1.21.
Institutional Trading of Shattuck Labs
A number of large investors have recently modified their holdings of STTK. Fisher Asset Management LLC bought a new stake in Shattuck Labs in the 3rd quarter valued at about $575,000. Profund Advisors LLC acquired a new position in Shattuck Labs during the 3rd quarter valued at about $195,000. ProShare Advisors LLC bought a new position in Shattuck Labs in the 3rd quarter worth about $70,000. China Universal Asset Management Co. Ltd. grew its position in Shattuck Labs by 74.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 25,600 shares of the company’s stock worth $167,000 after purchasing an additional 10,959 shares during the last quarter. Finally, Pinnacle Associates Ltd. grew its position in Shattuck Labs by 12.2% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,099,779 shares of the company’s stock worth $14,320,000 after purchasing an additional 228,337 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.
About Shattuck Labs
Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.
Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.
Read More
- Five stocks we like better than Shattuck Labs
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
